- Home
- NEN vs ZURA Comparison
NEN vs ZURA Comparison
Compare NEN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
NEN
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
Company Overview
Basic Information| Metric | NEN | ZURA |
|---|---|---|
| Founded | 1977 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.9M | 252.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEN | ZURA |
|---|---|---|
| Price | $65.01 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 1.3K | ★ 1.0M |
| Earning Date | 03-12-2026 | 11-13-2025 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $87,362,592.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.54 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $62.10 | $0.97 |
| 52 Week High | $84.00 | $6.63 |
Technical Indicators
Market Signals| Indicator | NEN | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 68.66 |
| Support Level | $62.41 | $4.41 |
| Resistance Level | $65.30 | $6.63 |
| Average True Range (ATR) | 0.65 | 0.66 |
| MACD | 0.26 | 0.10 |
| Stochastic Oscillator | 64.61 | 85.44 |
Price Performance
Historical ComparisonAbout NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.